CTOs on the Move

CSL Behring

www.cslbehring.com

 
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Steven Yannelli
 Director of Application Security and Compliance Profile

Similar Companies

Centessa

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.

Amgenix International

Amgenix International is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cylene Pharmaceuticals

Cylene Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pherin Pharmaceuticals Inc

Pherin Pharmaceuticals Inc is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TearClear

TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.